Effect of Dapagliflozin on Interleukin 10 Compared to High Density Lipoprotein As a Prognosis in Septic Patients
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 64
- 主要终点
- the anti-inflammatory effect of dapagliflzin
研究概览
简要总结
The goal of this observational study is to learn about the long-term effects of dapagliflozin as anti-inflammatory agents to improve organ dysfunction and decrease mortality on patients of both genders ageing 18 years or above with sepsis.
1ry Outcome: The anti-inflammatory effect of dapagliflozin in patients with sepsis evaluated by: Effect on inflammatory markers (IL-10).
2ry Outcomes:
- Severity of sepsis evaluated by the SOFA score.
- Prognostic value of HDL compared to IL-10 for multi organ failure and death in septic patients and their correlation to the severity of sepsis.
- ICU mortality &hospital length stay.
详细描述
64 Patients fulfilling the criteria for sepsis admitted to ICU will be allocated into 2 groups (32 patients in each group):
- Dapagliflozin group: Patients will receive dapagliflozin at a dosage of 10mg mixed with 10ml water at the time of admission for 7 days (or until ICU discharge, whichever comes first).
- Placebo group: Patients will receive vitastress tab .
The solutions of the study medications will be prepared by a hospital pharmacist and the medication will be administrated through the nasogastric tube in patients with disorder of consciousness or swallowing deficit.
Dapagliflozin will be stopped if the patients enter in more than one episode of severe hypoglycemia (≤50mg/dL) or occurrence of euglycemic diabetic ketoacidosis, defined by high anion gap metabolic acidosis and ketone bodies in the urine. Also the drug will be withheld if idiosyncratic drug reactions, such as DRESS syndrome (drug rash with eosinophilia and systemic symptoms) or allergic reaction to dapagliflozin has been occurred and if there is any need for absolute fasting and/or inability to access the enteral route for the drug.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •64 adult patients of both sex, over the age of 18 years who were admitted to the ICU with sepsis and those who developed sepsis in the ICU.
排除标准
- •Patient's refusal, pregnant and lactating patients.
- •Known allergy or intolerance to dapagliflozin.
- •Unable to receive enteral medication& patients with chronic liver disease.
- •Patients with malabsorption disorders & or receipt of total parenteral nutrition and on treatment with statins.
- •6. Patients with a history of familial hyperlipidemia.
- •End-stage renal disease (ESRD) on regular dialysis.
- •Type 1 diabetes.
结局指标
主要结局
the anti-inflammatory effect of dapagliflzin
时间窗: 7 days
Effect on inflammatory markers (IL-10).
The anti-inflammatory effect of dapagliflozin in patients with sepsis
时间窗: baseline
Effect of dapagliflozin in sepsis evaluated by: Effect on inflammatory markers (IL-10).
次要结局
未报告次要终点
研究者
Mostafa Ragab Lokai Shahat
Assistant lecturer of Anesthesia and Intensive Care
Minia University